Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CAO Michael P. Dube sold 1,372 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $16,710.96. Following the transaction, the chief accounting officer now owns 45,640 shares in the company, valued at approximately $555,895.20. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
NTLA stock traded down $0.33 on Tuesday, reaching $12.47. 2,355,020 shares of the company were exchanged, compared to its average volume of 2,637,028. The firm has a market capitalization of $1.27 billion, a PE ratio of -2.29 and a beta of 1.83. The stock's fifty day moving average price is $14.01 and its 200 day moving average price is $19.28. Intellia Therapeutics, Inc. has a 12 month low of $11.34 and a 12 month high of $34.87.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. During the same period last year, the business earned ($1.38) earnings per share. The firm's quarterly revenue was down 24.1% compared to the same quarter last year. As a group, research analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.
A number of brokerages recently issued reports on NTLA. Barclays decreased their target price on Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a report on Friday, November 8th. Stifel Nicolaus cut their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a report on Wednesday, September 11th. Robert W. Baird decreased their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. Finally, The Goldman Sachs Group dropped their price target on Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $54.94.
Check Out Our Latest Report on Intellia Therapeutics
A number of institutional investors have recently bought and sold shares of NTLA. EverSource Wealth Advisors LLC increased its stake in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth about $54,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after buying an additional 794 shares in the last quarter. Finally, KBC Group NV grew its stake in Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company's stock worth $77,000 after buying an additional 1,020 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.